Amylyx reports Phase 3 LUCIDITY trial shows 55% drop in hypoglycemic events

Amylyx Pharmaceuticals announced that its Phase 3 LUCIDITY trial of avexitide met the primary endpoint, cutting the composite hypoglycemic event rate by 55% versus placebo. The trial enrolled 78 adults with post‑bariatric hypoglycemia, randomised 3:2 to a daily 90 mg subcutaneous dose of avexitide or placebo, and achieved statistically significant reductions across all prespecified secondary endpoints. The company said it will file a New Drug Application by the end of 2026 and is targeting a commercial launch in 2027 if approved.

The company expects the NDA filing by year‑end to move avexitide toward potential FDA approval and a 2027 market launch, which could create a new revenue stream for Amylyx (the company says).

  • 1The trial reduced the composite hypoglycemic event rate by 55% versus placebo.
  • 2Adjusted event rates were 0.55 events per week on avexitide and 1.24 events per week on placebo (p=0.0000034).
  • 3The study enrolled 78 adult participants with post‑bariatric hypoglycemia.
  • 4Participants were randomised 3:2 to avexitide 90 mg daily or placebo.
  • 5More than 90% of participants completed the 16‑week double‑blind phase (45/47 avexitide, 28/31 placebo).
  • 6Amylyx plans to submit an NDA by the end of 2026 and aims for a 2027 launch if approved.

Sources